Vincerx【VINC】銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.2682

買値

0.2622

売値

0.2682

出来高

337,894

0.2613 日の範囲 0.29

0.2425 52 週間の範囲 9.3722

時価総額

前日終値

0.289

始値

0.2801

時刻

100

0.2682

最終取引時間

03:55:41

財務取引量

US$ 91,373

VWAP

0.270419

平均取引量 (3 か月)

547,144

発行済株式数

33,555,903

配当利回り

PER

-15.88

1 株当たり利益 (EPS)

-1.2

歳入

純利益

-40.16M

Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are primarily conducted in the United States. It focuses to develop, u... Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are primarily conducted in the United States. It focuses to develop, use, manufacture, commercialize, sublicense and distribute a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation/next-generation ADC platform. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Blank Checks

ウェブサイト

vincerx.com

本社

Wilmington, Delaware, USA

設立

2021

Vincerx Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker VINC. The last closing price for Vincerx was US$0.29. Over the last year, Vincerx shares have traded in a share price range of US$ 0.2425 to US$ 9.3722.

Vincerx currently has 33,555,903 shares in issue. The market capitalisation of Vincerx is US$9.70 million. Vincerx has a price to earnings ratio (PE ratio) of -15.88.

Form 8-K - Current report

Vincerx Pharma Reports Third Quarter 2024 Financial Results

Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed Phase 1...

Form PRE 14A - Other preliminary proxy statements

Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates

VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program’s potential and validating the VersAptx™...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.0127	4.97064579256	0.2555	0.296575	0.248201	255651	0.27942345	CS
4	-0.0868	-24.4507042254	0.355	0.38	0.2425	346049	0.30236055	CS
12	-0.4718	-63.7567567568	0.74	0.7837	0.2425	547144	0.45108364	CS
26	-0.3851	-58.9468850452	0.6533	0.8586	0.2425	355768	0.52247709	CS
52	-0.4218	-61.1304347826	0.69	9.3722	0.2425	618483	1.89303881	CS
156	-10.3318	-97.4698113208	10.6	11.26	0.2425	289003	1.97393214	CS
260	-19.8518	-98.6669980119	20.12	26.75	0.2425	246463	3.50159956	CS

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
CTNTCheetah Net Supply Chain Service Inc	US$ 5.318 (184.39%)	107.59M
ZJKZJK Industrial Company Ltd	US$ 14.37 (126.66%)	20.59M
GWAVGreenwave Technology Solutions Inc	US$ 0.6041 (65.51%)	404.06M
JANXJanux Therapeutics Inc	US$ 62.10 (54.55%)	5.33M
JYDJayud Global Logistics Ltd	US$ 1.03 (53.71%)	9.42M
REVBRevelation Biosciences Inc	US$ 0.5649 (-40.53%)	3.88M
OMEXOdyssey Marine Exploration Inc	US$ 0.48335 (-35.14%)	3.55M
STSSSharps Technology Inc	US$ 2.2308 (-33.48%)	380.92k
GELSGelteq Ltd	US$ 2.6491 (-30.66%)	225.23k
MOBXMobix Labs Inc	US$ 1.0022 (-28.42%)	1.23M
GWAVGreenwave Technology Solutions Inc	US$ 0.6035 (65.34%)	404.24M
SMCISuper Micro Computer Inc	US$ 41.22 (-1.86%)	171.03M
CTNTCheetah Net Supply Chain Service Inc	US$ 5.3101 (183.96%)	109.14M
CHRSCoherus BioSciences Inc	US$ 1.785 (30.29%)	104.76M
NVDANVIDIA Corporation	US$ 139.3338 (0.51%)	102.78M